WINNERSH, England, Sept. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE: VER, Nasdaq: VNLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Frova® (frovatriptan succinate) 2.5 mg tablets for the short-term (six days per month) prevention of menstrual migraine (MM). Acceptance for filing indicates recognition by the FDA that the submission is complete and warrants full review of the data needed to assess the safety and efficacy of Frova® for the short-term prevention of MM.
